Azathioprin in der Therapie der multiplen Sklerose:
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Language: | German |
| Published: |
Bremen [u.a.]
UNI-MED-Verl.
2000
|
| Series: | UNI-MED-Congress
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Item Description: | Literaturangaben |
| Physical Description: | 63 S. graph. Darst. |
| ISBN: | 3895993069 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV013202614 | ||
| 003 | DE-604 | ||
| 005 | 20001018 | ||
| 007 | t | ||
| 008 | 000606s2000 gw d||| |||| 00||| ger d | ||
| 016 | 7 | |a 959099646 |2 DE-101 | |
| 020 | |a 3895993069 |c Pp. : DM 79.80 |9 3-89599-306-9 | ||
| 035 | |a (OCoLC)46872865 | ||
| 035 | |a (DE-599)BVBBV013202614 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a ger | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-355 | ||
| 084 | |a YG 6015 |0 (DE-625)153507:12921 |2 rvk | ||
| 100 | 1 | |a Haas, Judith |e Verfasser |0 (DE-588)108679659 |4 aut | |
| 245 | 1 | 0 | |a Azathioprin in der Therapie der multiplen Sklerose |c [Judith Haas. Unter Mitarb. von F. Heidenreich ...] |
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2000 | |
| 300 | |a 63 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED-Congress | |
| 500 | |a Literaturangaben | ||
| 650 | 4 | |a Azathioprine |x therapeutic use |v Congresses | |
| 650 | 4 | |a Azathioprine |x therapeutic use |v Practice Guideline | |
| 650 | 4 | |a Immunosuppressive Agents |x therapeutic use |v Congresses | |
| 650 | 4 | |a Immunosuppressive Agents |x therapeutic use |v Practice Guideline | |
| 650 | 4 | |a Multiple Sclerosis |x drug therapy |v Congresses | |
| 650 | 4 | |a Multiple Sclerosis |x drug therapy |v Practice Guideline | |
| 650 | 0 | 7 | |a Azathioprin |0 (DE-588)4143781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Multiple Sklerose |0 (DE-588)4040693-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1998 |z Hannover |2 gnd-content | |
| 655 | 2 | |a Practice Guideline | |
| 689 | 0 | 0 | |a Multiple Sklerose |0 (DE-588)4040693-3 |D s |
| 689 | 0 | 1 | |a Azathioprin |0 (DE-588)4143781-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008995463&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-008995463 | ||
Record in the Search Index
| _version_ | 1804127903465603072 |
|---|---|
| adam_text | Inhaltsverzeichnis
1. Gedenkworte am 10.1.1998 in Hannover 10
2. Der natürliche Verlauf und die genetische Belastung bei Multipler Sklerose 14
3. Stellenwert der Liquoranalyse bei der Multiplen Sklerose 18
3.1. Nutzen und Probleme der Liquordiagnostik bei der Multiplen Sklerose 18
3.2. Natürlicher Verlauf der Routineparameter im Liquor bei der MS 19
3.2.1. Zellzahl 19
3.2.2. CSF/Serum Albumin Quotient 20
3.2.3. Intrathekale IgG Synthese 20
3.3. Zusammenhänge zwischen routinemäßig erfaßten Liquor Parametern und klinischen Variablen bei
der MS 20
3.3.1. Albuminquotient 20
3.3.2. Intrathekale IgG Synthese 20
3.4. Auswirkung von Histopathochemie und klinischen Kenngrößen auf die Zusammensetzung des
Liquors 22
3.5. Therapieeffekte 24
4. Stellenwert der Liquorzytologie bei Multipler Sklerose 30
4.1. Zytologie in der klinischen Diagnostik 30
4.2. Liquorzytologie in der MS Forschung 31
5. Immunsuppressive Behandlung der Multiplen Sklerose mit Azathioprin 34
5.1. Einleitung 34
5.2. Struktur und Wirkungsmechanismus von Azathioprin 34
5.3. Offene Therapiestudien zur Wirksamkeit von Azathioprin 34
5.4. Deutsche MultiCenter Studie Cyclosporin A versus Azathioprin 38
5.5. Einfluß von Azathioprin auf immunologische Parameter 39
5.6. Kernspintomographie unter Azathioprin 40
5.7. Nebenwirkungen der Azathioprin Therapie 41
5.8. Derzeitiger Stellenwert von Azathioprin in der Therapie der Multiplen Sklerose 43
5.9. Zusammenfassung 44
6. Neue immunmodulierende und suppressive Therapien bei MS 50
6.1. Vorbeugen von Schüben und Progression 50
6.2. Behandlung des Schubes 51
7. Experimentelle Therapien der MS 54
7.1. Einleitung 54
7.2. Therapieziele bei MS 55
7.3. Zytokintherapie 55
7.3.1. Weiterentwicklung der Interferontherapie 55
7.3.2. Antagonisierung von Tumor Nekrose Faktor alpha (TNF alpha) 56
7.3.3. PharmakologischeTNF lnhibitoren 56
7.3.4. Biologische TNF Inhibitoren 56
7.4. Inhibitorische Cytokine 57
7.5. Hemmung von Zeiladhäsionsmolekülen 57
7.6. Kostimulatorische Moleküle 58
7.7. Proteinase Inhibitoren 58
7.8. Inhibition von T Zellen 58
7.9. Hemmung Ag präsentierender Zellen 58
7.10. Altered Peptide Ligands 59
7.11. Orale Toleranz 59
7.12. T Zell Vakzination 59
7.13. Stammzelltransplantation bei MS 60
7.14. Zusammenfassung 60
Index 65
|
| any_adam_object | 1 |
| author | Haas, Judith |
| author_GND | (DE-588)108679659 |
| author_facet | Haas, Judith |
| author_role | aut |
| author_sort | Haas, Judith |
| author_variant | j h jh |
| building | Verbundindex |
| bvnumber | BV013202614 |
| classification_rvk | YG 6015 |
| ctrlnum | (OCoLC)46872865 (DE-599)BVBBV013202614 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01986nam a2200481 c 4500</leader><controlfield tag="001">BV013202614</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20001018 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">000606s2000 gw d||| |||| 00||| ger d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">959099646</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3895993069</subfield><subfield code="c">Pp. : DM 79.80</subfield><subfield code="9">3-89599-306-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)46872865</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV013202614</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 6015</subfield><subfield code="0">(DE-625)153507:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Haas, Judith</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)108679659</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Azathioprin in der Therapie der multiplen Sklerose</subfield><subfield code="c">[Judith Haas. Unter Mitarb. von F. Heidenreich ...]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">63 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED-Congress</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Azathioprine</subfield><subfield code="x">therapeutic use</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Azathioprine</subfield><subfield code="x">therapeutic use</subfield><subfield code="v">Practice Guideline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppressive Agents</subfield><subfield code="x">therapeutic use</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppressive Agents</subfield><subfield code="x">therapeutic use</subfield><subfield code="v">Practice Guideline</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Sclerosis</subfield><subfield code="x">drug therapy</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Sclerosis</subfield><subfield code="x">drug therapy</subfield><subfield code="v">Practice Guideline</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Azathioprin</subfield><subfield code="0">(DE-588)4143781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1998</subfield><subfield code="z">Hannover</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Practice Guideline</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Multiple Sklerose</subfield><subfield code="0">(DE-588)4040693-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Azathioprin</subfield><subfield code="0">(DE-588)4143781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008995463&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008995463</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1998 Hannover gnd-content Practice Guideline |
| genre_facet | Konferenzschrift 1998 Hannover Practice Guideline |
| id | DE-604.BV013202614 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:40:44Z |
| institution | BVB |
| isbn | 3895993069 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008995463 |
| oclc_num | 46872865 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 63 S. graph. Darst. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED-Congress |
| spelling | Haas, Judith Verfasser (DE-588)108679659 aut Azathioprin in der Therapie der multiplen Sklerose [Judith Haas. Unter Mitarb. von F. Heidenreich ...] Bremen [u.a.] UNI-MED-Verl. 2000 63 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier UNI-MED-Congress Literaturangaben Azathioprine therapeutic use Congresses Azathioprine therapeutic use Practice Guideline Immunosuppressive Agents therapeutic use Congresses Immunosuppressive Agents therapeutic use Practice Guideline Multiple Sclerosis drug therapy Congresses Multiple Sclerosis drug therapy Practice Guideline Azathioprin (DE-588)4143781-0 gnd rswk-swf Multiple Sklerose (DE-588)4040693-3 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1998 Hannover gnd-content Practice Guideline Multiple Sklerose (DE-588)4040693-3 s Azathioprin (DE-588)4143781-0 s DE-604 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008995463&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Haas, Judith Azathioprin in der Therapie der multiplen Sklerose Azathioprine therapeutic use Congresses Azathioprine therapeutic use Practice Guideline Immunosuppressive Agents therapeutic use Congresses Immunosuppressive Agents therapeutic use Practice Guideline Multiple Sclerosis drug therapy Congresses Multiple Sclerosis drug therapy Practice Guideline Azathioprin (DE-588)4143781-0 gnd Multiple Sklerose (DE-588)4040693-3 gnd |
| subject_GND | (DE-588)4143781-0 (DE-588)4040693-3 (DE-588)1071861417 |
| title | Azathioprin in der Therapie der multiplen Sklerose |
| title_auth | Azathioprin in der Therapie der multiplen Sklerose |
| title_exact_search | Azathioprin in der Therapie der multiplen Sklerose |
| title_full | Azathioprin in der Therapie der multiplen Sklerose [Judith Haas. Unter Mitarb. von F. Heidenreich ...] |
| title_fullStr | Azathioprin in der Therapie der multiplen Sklerose [Judith Haas. Unter Mitarb. von F. Heidenreich ...] |
| title_full_unstemmed | Azathioprin in der Therapie der multiplen Sklerose [Judith Haas. Unter Mitarb. von F. Heidenreich ...] |
| title_short | Azathioprin in der Therapie der multiplen Sklerose |
| title_sort | azathioprin in der therapie der multiplen sklerose |
| topic | Azathioprine therapeutic use Congresses Azathioprine therapeutic use Practice Guideline Immunosuppressive Agents therapeutic use Congresses Immunosuppressive Agents therapeutic use Practice Guideline Multiple Sclerosis drug therapy Congresses Multiple Sclerosis drug therapy Practice Guideline Azathioprin (DE-588)4143781-0 gnd Multiple Sklerose (DE-588)4040693-3 gnd |
| topic_facet | Azathioprine therapeutic use Congresses Azathioprine therapeutic use Practice Guideline Immunosuppressive Agents therapeutic use Congresses Immunosuppressive Agents therapeutic use Practice Guideline Multiple Sclerosis drug therapy Congresses Multiple Sclerosis drug therapy Practice Guideline Azathioprin Multiple Sklerose Konferenzschrift 1998 Hannover Practice Guideline |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008995463&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT haasjudith azathioprinindertherapiedermultiplensklerose |